Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MRNA-1769 by Moderna for Smallpox: Likelihood of Approval
MRNA-1769 is under clinical development by Moderna and currently in Phase II for Smallpox. According to GlobalData, Phase II drugs...
MRNA-1011.2 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1011.2 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1403 by Moderna for Norovirus Infections: Likelihood of Approval
MRNA-1403 is under clinical development by Moderna and currently in Phase II for Norovirus Infections. According to GlobalData, Phase II...
MRNA-1405 by Moderna for Norovirus Infections: Likelihood of Approval
MRNA-1405 is under clinical development by Moderna and currently in Phase II for Norovirus Infections. According to GlobalData, Phase II...
MRNA-1608 by Moderna for Genital Herpes: Likelihood of Approval
MRNA-1608 is under clinical development by Moderna and currently in Phase II for Genital Herpes. According to GlobalData, Phase II...
MRNA-2752 by Moderna for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
MRNA-2752 is under clinical development by Moderna and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According...
MRNA-3210 by Moderna for Phenylketonuria (PKU): Likelihood of Approval
MRNA-3210 is under clinical development by Moderna and currently in Phase II for Phenylketonuria (PKU). According to GlobalData, Phase II...
MRNA-1365 by Moderna for Human Metapneumovirus Infections: Likelihood of Approval
MRNA-1365 is under clinical development by Moderna and currently in Phase I for Human Metapneumovirus Infections. According to GlobalData, Phase...
MRNA-1012.1 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1012.1 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1011.1 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1011.1 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H3N2 Subtype Infections. According...
MRNA-1083 by Moderna for Influenzavirus B Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenzavirus B Infections. According to GlobalData, Phase...
MRNA-1083 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H1N1 Subtype Infections. According...
MRNA-1010 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According...
MRNA-1010 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Seasonal Influenza. According to GlobalData, Phase III...
MRNA-1010 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections. According...
MRNA-0184 by Moderna for Congestive Heart Failure (Heart Failure): Likelihood of Approval
MRNA-0184 is under clinical development by Moderna and currently in Phase I for Congestive Heart Failure (Heart Failure). According to...
MRNA-4157 by Moderna for Metastatic Melanoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-3927?
MRNA-3927 is a gene therapy commercialized by Moderna, with a leading Phase II program in Propionic Acidemia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-1647?
MRNA-1647 is a mrna vaccine commercialized by Moderna, with a leading Phase III program in Cytomegalovirus (HHV-5) Infections. According to...